for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Myomo Inc

MYO

Latest Trade

10.34USD

Change

0.19(+1.87%)

Volume

24,100

Today's Range

10.16

 - 

10.49

52 Week Range

3.46

 - 

18.88

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
10.15
Open
10.16
Volume
24,100
3M AVG Volume
1.62
Today's High
10.49
Today's Low
10.16
52 Week High
18.88
52 Week Low
3.46
Shares Out (MIL)
5.60
Market Cap (MIL)
56.88
Forward P/E
-5.11
Dividend (Yield %)
--

Next Event

Myomo Inc at Sidoti & Company Virtual Investor Conference

Latest Developments

More

Myomo Reports First Quarter 2021 Financial Results

Myomo Enters Renewed Employment Agreement With CEO

Myomo Reports Fourth Quarter And Full Year 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Myomo Inc

Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.

Industry

Medical Equipment & Supplies

Contact Info

137 PORTLAND STREET, 4TH FLOOR

BOSTON, MA

02114

United States

+1.617.9969058

http://myomo.com/

Executive Leadership

Steve Kelly

Founder, Chairman of the Board, President and Chief Operating Officer

Paul R. Gudonis

Chief Executive Officer, Director

David A. Henry

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Jonathan Naft

General Manager - O&P

Fredrick Nahm

Medical Director

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-25.200

2019

-19.350

2020

-3.670

2021(E)

-1.988
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.38
Price To Book (MRQ)
3.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-74.96
Return on Equity (TTM)
-58.22

Latest News

Latest News

BRIEF-Myomo Resumes Fitting MyoPro Patients And Deliveries As States Begin To Re-Open

* MYOMO RESUMES FITTING MYOPRO PATIENTS AND DELIVERIES AS STATES BEGIN TO RE-OPEN AFTER COVID-19 SHUTDOWNS

BRIEF-Myomo Reports Quarterly Loss Per Share Of $2.51

* Q1 REVENUE $1.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $855,000

BRIEF-Myomo Reports Accelerating Growth In Myopro Pipeline

* MYOMO REPORTS ACCELERATING GROWTH IN MYOPRO PIPELINE AND RECORD BACKLOG IN THE FIRST QUARTER OF 2020, PROVIDES UPDATE ON THE BUSINESS IMPACT OF COVID-19

BRIEF-Myomo Reports Q4 Loss Per Share Of $4.81

* MYOMO REPORTS 2019 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS FEATURING RECORD REVENUE AND GROSS MARGINS

BRIEF-Myomo Announces Closing Of Public Offering

* MYOMO ANNOUNCES CLOSING OF PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Myomo Signs Nationwide Payer Network Agreement With Homelink

* MYOMO® SIGNS NATIONWIDE PAYER NETWORK AGREEMENT WITH HOMELINK

BRIEF-Myomo Inc - Announced Pricing Of An Underwritten Public Offering Of 2.1 Million Shares Of Common Stock

* MYOMO INC - ANNOUNCED PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 2.1 MILLION SHARES OF COMMON STOCK

BRIEF-Myomo Sees Q4 Revenue $1.4 Million To $1.5 Million

* MYOMO REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2019 RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up